Introduction
Ovarian cancer represents a relatively chemosensitive solid tumour, with responsiveness to a range of agents (Reed et al., 1995) . Cisplatin is the mainstay of drug treatment and is one of the most active single agents. However, the overall outcome for patients remains unsatisfactory and the emergence of drug resistance is a major factor in treatment failure (Kaye, 1996) . It is generally accepted that DNA is a crucial target for the chemotherapeutic action of cisplatin (Zamble and Lippard, 1995) . The main DNA lesions formed by cisplatin are intrastrand crosslinks between closely adjacent purine bases; 1,2 crosslinks comprise about 90% and 1,3 crosslinks account for a further 5% (Fichtinger-Schepman et al., 1985) . Extracts of human cells eciently remove the latter lesions from DNA by nucleotide excision repair (Moggs et al., 1996) , but the 1,2 crosslinks are relatively refractory to removal by this pathway (Szymkowski et al., 1992) .
Inability to couple DNA damage to an apoptotic signal pathway or biochemical defects in the pathway may lead to cisplatin resistance. Recent observations lend support to the hypothesis of a direct role for mismatch repair in coupling cisplatin damage to an apoptotic response and lack of mismatch repair leading to cisplatin resistance. Firstly, cisplatin-resistant ovarian cell lines have been shown to acquire a microsatellite instability (RER + ) phenotype and to be defective in strand-speci®c mismatch repair . Secondly, it has been shown that the mismatch repair protein complex MutSa can recognise and bind to the cisplatin 1,2 crosslink (Mello et al., 1996; Duckett et al., 1996) . Thirdly, resistant lines which acquire an RER + phenotype and lose mismatch repair activity also lose the ability to undergo cisplatin induced apoptosis, which is associated with loss of p53 function Anthoney et al., 1996) . Lastly, human colon and endometrial cancer cell lines that are de®cient in hMLH1 or hMSH2 function are more resistant to cisplatin than sublines in which the mismatch repair de®ciency is complemented by chromosome transfer .
Defective mismatch repair has been suggested to occur in 15 ± 20% of sporadic ovarian tumours and two separate studies have raised the possibility that the presence of mismatch repair may have prognostic signi®cance due to its association with certain histological types of ovarian cancer (Fujita et al., 1995; King et al., 1995) . Defective mismatch repair also predicts poor prognosis for breast cancer tumours (Paulson et al., 1996) , although predicts good prognosis for colon tumours (Bubb et al., 1996) . In the present study we have examined the frequency of loss of expression of mismatch repair proteins in independent cisplatin resistant derivatives of a chemosensitive human ovarian cell line, as well as in untreated ovarian tumours compared to residual tumour at second look surgery after platinum based chemotherapy.
The development of drug resistance through loss of mismatch repair competence has a precedent in the development of resistance (known as methylation tolerance) to DNA methylation damage in human cells (Karran and Bignami, 1994) . The study of such methylation tolerant lines suggests that the mismatch repair system interacts with the G2 cell cycle checkpoint in response to 6-thioguanine or methylating agent induced DNA lesions (Hawn et al., 1995) . Cisplatin treatment of cells can inhibit their progression through the cell cycle by inducing a G2 arrest and which has been implicated in cisplatin induced apoptosis (Eastman, 1990 ). Therefore we have examined whether the cisplatin selected lines with loss of mismatch repair have a defective cisplatin induced G2 arrest and are cross-resistant to alkylating agents and 6-thioguanine.
Results

Mismatch repair gene expression in cisplatin resistant ovarian tumour lines
Cisplatin resistant derivatives of human ovarian carcinoma cell lines frequently acquire a microsatellite instability (RER + ) phenotype . Furthermore, in contrast to parental cells, extracts of a doxorubicin-resistant and two independent cisplatinresistant derivatives are defective in strand-speci®c mismatch repair . We now show that the majority of cisplatin resistant derivatives of A2780 (9/10 lines) show loss of the hMLH1 and hPMS2 subunits of MutLa (Figure 1a ). These resistant lines were isolated in a manner to ensure their independence (see Materials and methods). The hMSH2 and hMSH6 subunits of MutSa are detectable in all lines. The lack of hMLH1 protein in the cisplatin-resistant lines, except MCP8, was con®rmed by immunohistochemistry (data not shown).
As assayed by semi-quantitative RT ± PCR ( Figure  1b ) or Northern analysis (data not shown), the levels of hMLH1 mRNA were reduced in all the cisplatin resistant derivatives, except MCP8. RT ± PCR of MCP5 did show some detectable, but reduced, hMLH1 mRNA. None of the lines showed any reduction in hPMS2 or hMSH2 mRNA levels. Thus nine out of ten independent cisplatin-resistant derivatives of A2780 have lost hMLH1 expression. The reduced levels of the hPMS2 subunit of MutLa observed by immunoassays presumably represent instability of the hPMS2 subunit in the absence of its partner, hMLH1, in the heterodimer.
The frequent loss of hMLH1 expression observed in the cisplatin and doxorubicin resistant lines may suggest that the parental A2780 cells are hemizygous for hMLH1. However, as determined by¯uorescent in situ hybridisation using a genomic clone of hMLH1, the A2780 line has two copies of hMLH1 ( Figure 2 ) and are heterozygous for microsatellite alleles closely linked to the hMLH1 locus (data not shown). Furthermore, A2780/cp70, A2780/MCP1 and A2780/AD lines all also have two copies of hMLH1 ( Figure 2 ) and maintain heterozygosity at closely linked microsatellite loci. FISH analysis using Chromosome 3 paint shows that A2780/MCP1 has acquired a translocation of one chromosome 3, but the breakpoint appears distinct from the hMLH1 locus.
Mismatch repair protein expression in ovarian tumours
Microsatellite instability has been detected in 15 ± 20% of ovarian tumours, which will be a minimal estimate of the number of tumours lacking mismatch repair (Fujita et al., 1995; King et al., 1995) . Since we observe loss of expression of mismatch repair proteins, in particular hMLH1, to be closely associated with microsatellite instability in ovarian tumour cell line models, we have examined expression of hMLH1, hPMS2, hMSH6 and hMSH2 by immunoblot Western analysis in extracts of ovarian tumour extracts. Samples have been scored negative for immunologically recognisable protein if low or undetectable levels of protein were observed (for example, see Figure 3 ). All samples examined were positive for vinculin on the same immunoblot. Extracts from thirty-nine ovarian tumours which had not received any chemotherapy were examined (Table 1 ) and 10% were negative for hMLH1, 15% for hPMS2, 8% for hMSH2 and 5% for hMSH6. Overall 24% of tumours were negative for at least one of the mismatch repair proteins. We observe an increase in ovarian tumours immunologically were Western immunoblotted and analysed using antibodies to the mismatch repair proteins hMLH1, hPMS2, hMSH2 and hMSH6. Vinculin was used as an internal control for loading. The variations in hMSH2 and hMSH6 were not consistently observed in independent Westerns and are due to loading and transfer variation as shown by the vinculin levels. (b) Semi-quantitative RT ± PCR. cDNA was prepared from the cell lines and analysed by PCR using primers speci®c for hMLH1, hPMS2, hMSH2 and b-actin as shown. The number of rounds of PCR ampli®cation used were such that amount of product was proportional to amount of starting cDNA. Repeat preparations of cDNA gave similar results. AN3CA is an endometrial cell line known to be defective in hMLH1 expression Loss of hMLH1 expression in ovarian cancer R Brown et al negative for the hMLH1 subunit of the mismatch repair MutLa heterodimer in samples taken at second look laparotomy after chemotherapy (36%; 4/11), compared to untreated tumours (10%; 4/39). This is of borderline statistical signi®cance (P=0.059 using Fisher Exact Test). No signi®cant dierence is observed for hMSH2, hMSH6 or hPMS2. The tumours taken post-chemotherapy were from patients treated with both platinum and cyclophosphamide as previously described (Van der Zee et al., 1994) . The number of samples analysed before chemotherapy is too small to make any correlation with response to treatment. However, together with the data observed in the cisplatin resistant cell line models, the increase in the number of tumours negative for hMLH1 encourage larger studies to be done in ovarian tumours correlating mismatch repair protein expression with response to chemotherapy.
Alkylating agent tolerance in mismatch repair de®cient cisplatin and doxorubicin resistant ovarian lines
Cell lines de®cient in hMLH1 have previously been shown to be tolerant to DNA damage induced by (Koi et al., 1994) and the purine analogue 6-TG (Aquilina et al., 1990) . Restoration of mismatch repair in such cell lines can increase their sensitivity to MNNG (Koi et al., 1994) and cisplatin . As shown in Figure 4 , A2780 cells selected for cisplatin resistance, which are de®cient in hMLH1, are cross resistant to MNU and 6-thioguanine. In addition a doxorubicin resistant derivative of A2780, which also lacks mismatch repair activity, due to loss of hMLH1 expression , is also cross resistant to MNU and 6-TG (Figure 4) . O 6 -methylguanine, a major methylation product formed in DNA by MNU (Beranek, 1990) , can be repaired by ATase activity in cells. O6-BzG treatment of cells depletes ATase activity (Dolan et al., 1990) . The ATase activities of A2780 parental cells, the cisplatin resistant derivatives A2780/cp70 and MCP1 and the doxorubicin resistant derivative A2780/AD are shown in Table  2 . Treatment of these lines with 5 mM O 6 -BzG for 4 h completely depleted ATase activity. O 6 -BzG treatment of cells increased the sensitivity of all the lines to MNU (Table 2) , however, the resistant lines retained crossresistance to MNU compared to the parental A2780 even after depletion of ATase activity. These lines also retained cross-resistance to cisplatin after ATase depletion (data not shown). Thus hMLH1 de®cient cell lines, which were selected for cisplatin and doxorubicin resistance, have a methylating agent tolerant phenotype and show cross resistance to several clinically important cytotoxic anticancer agents.
Abrogated G2 arrest in hMLH1 de®cient cisplatin resistant lines
The decreased p53-mediated apoptosis observed in the cisplatin-resistant derivatives suggests that mismatch repair is necessary for engagement of cell death. It may also be predicted that other cellular responses to the damage will be abrogated in the hMLH1-de®cient, resistant lines. It has previously been suggested that the mismatch repair system interacts with the G2 cell cycle checkpoint in response to 6-thioguanine or methylating agent induced DNA lesions (Hawn et al., 1995) . Cisplatin treatment of cells can inhibit their progression through the cell cycle by inducing a G2 arrest and this G2 arrest has been implicated in cisplatin-induced apoptosis (Sorenson et al., 1990) . The eect of cisplatin treatment on cell cycle progression of the hMLH1 de®cient A2780/cp70 and MCP1 lines compared to the parental A2780 cells are shown in hMSH6 Figure 3 Western immunoblot of tumour cell extracts. Extracts were prepared from ovarian tumours and analysed by Western immunoblotting using antibodies to the mismatch repair proteins hMLH1, hMSH2, hPMS2 and hMSH6. Extracts from the tumour shown in lane 3 were scored negative for hMLH1 and hPMS2 expression, while the tumour extract in lane 2 was scored negative for hMSH6 Figure 2 ). Only samples with positive vinculin cross-reactivity on Western analysis of the same immuno-blot were included in the analysis. Loss of hMLH1 expression in ovarian cancer R Brown et al ionising radiation (Brown et al., 1993) . As shown in Figure 5 , A2780 cells also show a reduction in the number of cells entering DNA replication from G1 (early S) after cisplatin treatment, and this reduction is lost in the cisplatin resistant lines. Together, these observations support the idea that mismatch repair is necessary for the engagement of diverse cellular responses to cisplatin-induced DNA damage.
Discussion
We show that cisplatin and doxorubicin resistant derivatives of an ovarian tumour line are de®cient in hMLH1 mismatch repair protein and are crossresistant to the methylating agent MNU and to 6-thioguanine. These observations lead to the question: how does lack of mismatch repair confer drug resistance? In the case of O 6 -methylation it has been proposed that inappropriate attempts at mismatch correction lead to cell death (Karran and Bignami, 1994) . Thus cells acquire resistance due to the absence of such futile repair. However, we favour a model whereby cisplatin DNA adducts cause replication stalling in hMLH1 pro®cient cells, which leads to cell death; while the absence of hMLH1 allows replication bypass of the lesion and cell survival. It has been shown that cellular proliferation and hence presumably DNA replication is required for induction of apoptosis by cisplatin (Evans et al., 1994) . hMutSa recognises 1,2 cisplatin crosslinks in a duplex DNA in which the complementary DNA strand contains two C residues opposite a 1,2 diguanyl crosslink (Duckett et al., 1996) . However, this is a relatively poor substrate for hMutSa and a duplex molecule in which the platinated guanine residues are opposite non-complementary bases, is bound with much greater anity (Yamada et al., 1997) . Such structures can arise in the cell if platinum damaged DNA has undergone replication. Certain cisplatin-resistant human ovarian cells appear able to bypass cisplatin DNA intrastrand crosslinks during DNA replication (Mamenta et al., 1994) . The mechanisms leading to bypass are largely unknown, but the possibilities include recombinational mechanisms, as well as direct insertion of (possibly incorrect) nucleotides opposite the non-instructional platinated purines. In general, replicative by-pass of 1,2 diguanyl cisplatin adducts has been considered inecient and only DNA polymerase b appears capable of signi®cant by-pass of adducts of this type (Homann et al., 1995) . However, recent evidence indicates that the replicative polymerases d and e are indeed able to by-pass these adducts in structures that resemble replication forks (Homann et al., 1996) . One possible mechanism of cisplatin toxicity is that inability to by-pass this lesion ATase activity was measured as described in Materials and methods. The speci®c activity is expressed as fmole/mg protein. The percent of cells in G1 phase (G1; 2N DNA and negative for BUdR), early S-phase (ES; 2-3N DNA and positive for BUdR), late S-phase (LS; 3 ± 4N DNA and positive for BUdR) and G2/M phase (G2; 4N DNA and negative for BUdR) are shown after no drug treatment, as well as after treatment of cells with 20 mM or 40 mM cisplatin for 1 h. Cells were pulsed for 4 h with BUdR at the times shown after treatment. The values shown were calculated from the mean of at least two repeat measurements, analysing more than 20 000 events each in sensitive cells has an intrinsic probability of being lethal or of generating a signal that activates a pathway of cell death. Cisplatin injured cells are known to die via induction of the apoptotic pathway (Ormerod et al., 1994) , which in the A2780 cells used in the present study is dependent on functional p53 (Gallagher et al., 1997) . A direct corollary of this model is that cisplatin resistance may be acquired by reducing the probability of lethal events occurring, or of preapoptotic signals being generated, during replication, allowing replication by-pass and cell survival.
Tumour cell lines which regain hMLH1 expression after chromosome transfer have increased sensitivity to cisplatin and carboplatin, but not to analogues which are trans-isomers . Although restoration of either hMLH1 or hMSH2 activity can increase sensitivity of colon tumour lines to cisplatin , 9/10 of the independent cisplatin resistant tumour lines we have examined show loss of hMLH1. The one line which has not lost hMLH1 expression (MCP8) does appear to have an RER + phenotype (although only at one out of 11 microsatellite loci examined) and so the biochemical basis of this phenotype remains unclear . A signi®cant increase in the proportion of tumours lacking hMLH1 expression is also observed in residual tumour samples after platinum-based chemotherapy compared to before chemotherapy. Since lack of hMLH1 expression is observed in a doxorubicin resistant derivative of A2780 and in a cisplatin resistant derivative from a dierent ovarian tumour line , loss of hMLH1 expression may be critical in the development of drug resistance. Why this is the case remains to be resolved. The speci®c loss of hMLH1 expression may suggest that this protein has a role in response to DNA damage dierent from the other mismatch repair proteins. In support of this hypothesis, genetic inactivation of dierent mismatch repair genes can lead to dierent phenotypic eects in both yeast (Chambers et al., 1996) and mice (Edelmann et al., 1996) . Alternatively this may be a re¯ection of the genotype of the tumour cells. Since two copies of hMLH1 need to be inactivated, if ovarian tumour cells frequently lose one copy during tumorigenesis, then only one allele need to be inactivated during drug selection. However, the A2780, A2780/cp70, A2780/ MCP1 and A2780/AD lines all have two copies of hMLH1 as determined by¯uorescent in situ hybridisation using an genomic clone of hMLH1 and are heterozygous for microsatellite alleles closely linked to the hMLH1 locus. It is also possible that the frequent inactivation of hMLH1 is due to this locus being functionally hemizygous, perhaps due to cytosine methylation. However, treatment of A2780/cp70, A2780/AD and A2780/MCP1 with 5-azacytidine did not restore hMLH1 expression (data not shown).
Microsatellite instability has been shown to correlate with reduced survival and poor prognosis in breast cancer (Paulson et al., 1996) . Conversely, microsatellite instability correlates with good prognosis in colon cancer (Bubb et al., 1996) . These dierences may re¯ect the dierent impact of microsatellite instability on tumour progression as well as drug sensitivity. Microsatellite instability has been suggested to occur in 15 ± 20% of sporadic ovarian tumours and two separate studies have raised the possibility that the presence of mismatch repair may have prognostic signi®cance, although possible correlation with response to chemotherapy has not been explored (Fujita et al., 1995; King et al., 1995) . We observe 24% of ovarian tumours to be immunologically negative for at least one of the mismatch repair proteins. Van der Zee and colleagues studied four dierent molecular determinants of drug resistance (Pglycoprotein, Glutathione-S-Transferase-pi, c-erbB2 and p53) in the same ovarian carcinoma samples as the present study (van der Zee et al., 1995) . The presence of detectable p53 correlated signi®cantly with poorer survival, although was not an independent prognostic determinant. No correlation between p53 status and response to chemotherapy after three cycles of treatment was observed in 70 patients who underwent second look laparotomy. There also was no correlation with any of the other markers. The increase in the proportion of tumours negative for hMLH1 after chemotherapy may suggest that tumour cells lacking hMLH1 and which are resistant to cisplatin have survived the treatment. However, the residual tumour cells present after chemotherapy need not be truly resistant and the expression of hMLH1 in clinically de®ned resistant tumour remains to be determined. The data presented in the present study on hMLH1 expression are from a small number of ovarian tumours, but they should encourage much larger studies to be initiated.
Materials and methods
Cell lines, clonogenic drug-sensitivity assays and cell cycle analysis All cell lines were grown as monolayer cultures in RPMI 1640 medium with 10% foetal calf serum in 95% air/5% CO 2 at 378C and routinely checked for mycoplasma. The isolation of independent cisplatin resistant derivatives of A2780 has previously been described . The lines were isolated from individual clones of A2780 which were maintained and drug selected separately in order to ensure the independence of drug resistant lines. For clonogenic drug sensitivity assays, cells were seeded at 10 3 per plate and after 24 h exposed to drug for the times shown. 6-thioguanine (Sigma) was dissolved in 0.1 M NaOH, N-methyl-N-nitrosourea (MNU), (Sigma) and O 6 -benzylguanine (O 6 -BzG) were dissolved in DMSO. After incubation of the plates for 10 days, colonies were stained and counted.
To determine the concentration of O 6 -BzG needed to fully deplete ATase activity, cells were seeded at 10 6 and after 24 h exposed to 5, 10 or 15 mM O 6 -BzG, for 2 or 4 h and assayed for ATase activity as previously described (Morten and Margison, 1988) . Treatment with 5 mM O 6 -BzG for 4 h depleted ATase activity in all lines examined and was subsequently used in all clonogenic assays.
Proportions of cells in dierent phases of the cell cycle were analysed by pulsed incorporation of BrdUrd, propidium iodide staining and¯ow cytometric analysis as previously described (Brown et al., 1993) .
Immunoblotting
Cell extracts were prepared by lysing exponentially growing cells in 1% Nonidet P-40, 500 mM NaCl, 50 mM Tris (pH 7.5), and 1 mM dithiothreitol in the presence of protease inhibitors. The source of tumours and preparation of tumour extracts was as previously described (Van der Zee et al., 1994) . Protein concentrations were determined by the Bio-Rad (Richmond, CA) protein assay. Immunoblotting was carried out as previously described (Vojtesek et al., 1992) using mouse monoclonal antibodies against hMLH1 (Clone G168-15, Pharminogen), hPMS2 (Ab1, Calbiochem) and rabbit polyclonal antisera against hMSH2 and hMSH6 (kindly supplied by Dr J Jiricny). Immuno-reactivity was visualised by enhanced chemiluminesence (Amersham). All immunoblots were examined for levels of loading using a vinculin antibody (Sigma).
Semi-quantitative RT ± PCR cDNA was synthesised from 2 mg total RNA using the Superscript II Pre-ampli®cation kit (Gibco BRL) according to the manufacturers protocol. Oligo(dT) 12 ± 18 primers were used to prime the reverse transcription reaction and the resulting cDNA was treated with RNAaseH to remove residual RNA. 1 ± 2 ml of the reaction product was used as template in standard or Touchdown PCR ampli®cation using gene-speci®c DNA primers derived using the GCG PRIME programme and synthesised on an Applied Biosystems DNA synthesiser. The number of rounds of PCR ampli®cation used were in the linear range for product formation. Primer sequences used are given below.
FISH analysis
Probe labelling, in situ hybridisation and probe detection were performed as described previously (Murphy et al., 1995) using the Hybaid Omnislide system (Hybaid Ltd, Teddington, UK). Chromosome 3 paint was purchased from Appligene-Oncor (Durham, UK). A P1 clone containing hMLH1 (Papadopoulos et al., 1994) was used to make a biotin labelled probe against genomic hMLH1 sequence and detected as described previously (Murphy et al., 1995) . Fluorescence was analysed and images captured using a CCD camera. Normal lymphocyte interphase nuclei were used as hybridisation controls to ensure probe speci®city and that the hybridisation eciency was greater than 80%. Chromosome 3 gene copy number in individual cells was determined by FISH analysis of interphase nuclei. Quantitative evaluation of hybridisations was carried out on 50 nuclei according to previously described criteria.
